Novavax shares rise on animal study of infant infection vaccine

Novavax Inc. shares advanced in the extended session Tuesday after the vaccine developer announced a promising animal study for one of its vaccine candidates. Novavax shares rose 4.5% to $10.63. The company said pregnant guinea pigs given the vaccine candidate transferred protection to their offspring from respiratory syncytial virus, a lead cause of infant infection.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Leave a Reply